Bleeding after cardiopulmonary bypass remains a cause for concern, requiring reexploration of the chest in approximately 3 percent of patients who have had operations on the heart. We examined the possibility that this problem might be alleviated by desmopressin acetate (DDAVP), which increases the plasma level of von Willebrand factor and improves hemostasis in mild hemophilia and other conditions associated with defective platelet function. In a double-blind, prospective, randomized trial, we studied the effect of intraoperative desmopressin acetate in 70 patients undergoing various cardiac operations requiring cardiopulmonary bypass. Patients undergoing uncomplicated primary coronary-artery bypass grafting were not included. The drug significantly reduced mean operative and early postoperative blood loss (1317 +/- 486 ml in the treated group vs. 2210 +/- 1415 ml in the placebo group); of the 14 patients whose 24-hour blood loss exceeded 2000 ml, 11 had received the placebo. Plasma levels of von Willebrand factor were higher after desmopressin acetate than after placebo. Patients with the most bleeding had relatively low levels of von Willebrand factor before operation, suggesting a role for this factor in the hemorrhagic tendency induced by extracorporeal circulation. There were no untoward side effects of desmopressin acetate. We conclude that the administration of desmopressin acetate can be recommended to reduce blood loss in patients undergoing complex cardiac operations. The beneficial effect of the drug on hemostasis after cardiopulmonary bypass may be related to its effect on von Willebrand factor.
This article has been cited by other articles:
Mannucci, P. M., Levi, M.
(2007). Prevention and Treatment of Major Blood Loss. NEJM
356: 2301-2311
[Full Text]
Levy, J. H.
(2005). Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. Am J Health Syst Pharm
62: S15-S19
[Abstract][Full Text]
Pleym, H., Stenseth, R., Wahba, A., Bjella, L., Tromsdal, A., Karevold, A., Dale, O.
(2004). Prophylactic Treatment with Desmopressin Does Not Reduce Postoperative Bleeding After Coronary Surgery in Patients Treated with Aspirin Before Surgery. Anesth. Analg.
98: 578-584
[Abstract][Full Text]
Ozal, E., Kuralay, E., Bingol, H., Cingoz, F., Ceylan, S., Tatar, H.
(2002). Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis?. J. Thorac. Cardiovasc. Surg.
123: 539-543
[Abstract][Full Text]
Beholz, S., Liu, J., Thoelke, R., Spiess, C, Konertz, W.
(2001). Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement. Perfusion
16: 485-489
[Abstract]
Skubas, N. J., Despotis, G. J.
(2001). Optimal Management of Bleeding Complications After Cardiac Surgery. SEMIN CARDIOTHORAC VASC ANESTH
5: 217-228
[Abstract]
Oliver, W. C. Jr, Santrach, P. J., Danielson, G. K., Nuttall, G. A., Schroeder, D. R., Ereth, M. H.
(2000). Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations. Ann. Thorac. Surg.
70: 1923-1930
[Abstract][Full Text]
Ness, P. M.
(2000). Transfusion Medicine: An Overview and Update. Clin. Chem.
46: 1270-1276
[Abstract][Full Text]
Despotis, G. J., Goodnough, L. T.
(2000). Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann. Thorac. Surg.
70: S20-32
[Abstract][Full Text]
Mannucci, P. M.
(1998). Hemostatic Drugs. NEJM
339: 245-253
[Full Text]
Peterson, P., Hayes, T. E., Arkin, C. F., Bovill, E. G., Fairweather, R. B., Rock, W. A. Jr, Triplett, D. A., Brandt, J. T.
(1998). The Preoperative Bleeding Time Test Lacks Clinical Benefit: College of American Pathologists' and American Society of Clinical Pathologists' Position Article. Arch Surg
133: 134-139
[Abstract][Full Text]
Bidstrup, B. P.
(1997). Coronary Artery Bypass Graft Patency. SEMIN CARDIOTHORAC VASC ANESTH
1: 282-287
[Abstract]
Mannucci, P. M.
(1997). Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood
90: 2515-2521
[Full Text]
Despotis, G. J., Joist, J. H., Goodnough, L. T.
(1997). Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin. Chem.
43: 1684-1696
[Abstract][Full Text]
D'Ambra, M. N., Akins, C. W., Blackstone, E. H., Bonney, S. L., Cohn, L. H., Cosgrove, D. M., Levy, J. H., Lynch, K. E., Maddi, R.
(1996). APROTININ IN PRIMARY VALVE REPLACEMENT AND RECONSTRUCTION: A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. J. Thorac. Cardiovasc. Surg.
112: 1081-1089
[Abstract][Full Text]
Lanzkron, S. M., Bell, W. R.
(1996). State-of-the-Art Review : Management of Patients Who Require Invasive Procedures Immediately Following Thrombolytic Therapy. CLIN APPL THROMB HEMOST
2: 158-163
[Abstract]
Moulton, M. J., Creswell, L. L., Mackey, M. E., Cox, J. L., Rosenbloom, M.
(1996). REEXPLORATION FOR BLEEDING IS A RISK FACTOR FOR ADVERSE OUTCOMES AFTER CARDIAC OPERATIONS. J. Thorac. Cardiovasc. Surg.
111: 1037-1046
[Abstract][Full Text]
Katsaros, D., Petricevic, M., Snow, N. J., Woodhall, D. D., Van Bergen, R.
(1996). Tranexamic Acid Reduces Postbypass Blood Use: A Double-Blinded, Prospective, Randomized Study of 210 Patients. Ann. Thorac. Surg.
61: 1131-1135
[Abstract][Full Text]
Hornick, P., George, A.
(1996). Blood contact activation: pathophysiological effects and therapeutic approaches. Perfusion
11: 3-19
Levy, J. H., Pifarre, R., Schaff, H. V., Horrow, J. C., Albus, R., Spiess, B., Rosengart, T. K., Murray, J., Clark, R. E., Smith, P., Nadel, A., Bonney, S. L., Kleinfield, R.
(1995). A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting. Circulation
92: 2236-2244
[Abstract][Full Text]
Casas, J. I., Zuazu-Jausoro, I., Mateo, J., Oliver, A., Litvan, H., Muniz-Diaz, E., Aris, A., Caralps, J. M., Fontcuberta, J.
(1995). APROTININ VERSUS DESMOPRESSIN FOR PATIENTS UNDERGOING OPERATIONS WITH CARDIOPULMONARY BYPASS: A double-blind placebo-controlled study. J. Thorac. Cardiovasc. Surg.
110: 1107-1117
[Abstract][Full Text]
Rousou, J. A., Engelman, R. M., Flack, J. E. III, Deaton, D. W., Owen, S. G.
(1995). Tranexamic Acid Significantly Reduces Blood Loss Associated With Coronary Revascularization. Ann. Thorac. Surg.
59: 671-675
[Abstract][Full Text]
Despotis, G. J., Santoro, S. A., Spitznagel, E., Kater, K. M., Cox, J. L., Barnes, P., Lappas, D. G.
(1994). Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J. Thorac. Cardiovasc. Surg.
107: 271-279
[Abstract][Full Text]
Lethagen, S.
(1993). Desmopressin (DDAVP), tranexamic acid and haemostasis. Perfusion
8: 417-425
[Abstract]
Taylor, K. M
(1993). The scope of the problem. Perfusion
8: 1-5
[Abstract]
Weisel, R. D
(1993). Agents that modify haemostasis after cardiopulmonary bypass. Perfusion
8: 6-12
[Abstract]
Cosgrove, D. M
(1993). Use of aprotinin in repeat myocardial revascularization: Cleveland Clinic experience. Perfusion
8: 36-42
[Abstract]
Spence, R. K.
(1993). Transfusion Practices in Vascular Surgery. PERSPECT VASC SURG ENDOVASC THER
6: 14-43
Tixier, D., Loisance, D., Deleuze, P., Hillion, M., Jouault, H., Bajan, G., Cachera, J.
(1991). Blood saving in cardiac surgery: simple approach and tendencies. Perfusion
6: 265-273
Spyt, T., Weerasena, N., Bain, W., Lowe, G., Rumley, A.
(1990). The effects of desmopressin acetate (DDAVP) on haemostasis and blood loss in routine coronary artery bypass surgery: a randomized, double-blind trial I. Perfusion
5: 57-61
[Abstract]
Royston, D.
(1990). Aprotinin in open-heart surgery: background and results in patients having aortocoronary bypass grafts. Perfusion
5: 63-72
Kickler, T.
(1989). How Safe Are Transfusions? Measures to Increase Safety. J Intensive Care Med
4: 93-94
Bidstrup, B. P
(1988). Review article : Blood conservation in cardiac surgery: can drugs help?. Perfusion
3: 171-177
Previous
